Opthea (OPT) Stock Forecast, Price Target & Predictions
OPT Stock Forecast
Opthea stock forecast is as follows: an average price target of $14.00 (represents a 344.44% upside from OPT’s last price of $3.15) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.
OPT Price Target
The average price target for Opthea (OPT) is $14.00 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $14.00 to $14.00. This represents a potential 344.44% upside from OPT's last price of $3.15.
OPT Analyst Ratings
According to 5 Wall Street analysts, Opthea's rating consensus is 'Buy'. The analyst rating breakdown for OPT stock is 0 'Strong Buy' (0.00%), 4 'Buy' (80.00%), 1 'Hold' (20.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Opthea Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Dec 08, 2022 | - | H.C. Wainwright | $14.00 | $4.97 | 181.69% | 344.44% |
The latest Opthea stock forecast, released on Dec 08, 2022 by H.C. Wainwright company, set a price target of $14.00, which represents a 181.69% increase from the stock price at the time of the forecast ($4.97), and a 344.44% increase from OPT last price ($3.15).
Opthea Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $3.15 | $3.15 | $3.15 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of Opthea stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Opthea's last price of $3.15. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 03, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Apr 25, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| Sep 16, 2022 | Citigroup | Buy | Buy | Hold |
| Apr 26, 2022 | SVB Leerink | - | Outperform | Initialise |
| Apr 26, 2022 | Zacks Investment Research | - | Hold | Upgrade |
Opthea's last stock rating was published by H.C. Wainwright on Sep 03, 2024. The company gave OPT a "Buy" rating, the same as its previous rate.
Opthea Financial Forecast
Opthea Revenue Forecast
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|
| Revenue | - | - | - | - |
| Avg Forecast | $66.92K | $149.71K | $62.04K | $52.76K |
| High Forecast | $66.92K | $149.71K | $62.04K | $52.76K |
| Low Forecast | $66.92K | $149.71K | $62.04K | $52.76K |
| # Analysts | - | - | - | - |
| Surprise % | - | - | - | - |
Opthea's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. OPT's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Opthea EBITDA Forecast
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|
| # Analysts | - | - | - | - |
| EBITDA | - | - | - | - |
| Avg Forecast | $-66.92K | $-149.71K | $-62.04K | $-52.76K |
| High Forecast | $-66.92K | $-149.71K | $-62.04K | $-52.76K |
| Low Forecast | $-66.92K | $-149.71K | $-62.04K | $-52.76K |
| Surprise % | - | - | - | - |
undefined analysts predict OPT's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Opthea's previous annual EBITDA (undefined) of $NaN.
Opthea Net Income Forecast
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|
| # Analysts | - | - | - | - |
| Net Income | - | - | - | - |
| Avg Forecast | $-80.74M | $-101.60M | $191.97M | $-82.42M |
| High Forecast | $-80.74M | $-101.60M | $191.97M | $-82.42M |
| Low Forecast | $-80.74M | $-101.60M | $191.97M | $-82.42M |
| Surprise % | - | - | - | - |
Opthea's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. OPT's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Opthea SG&A Forecast
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|
| # Analysts | - | - | - | - |
| SG&A | - | - | - | - |
| Avg Forecast | $9.92M | $22.18M | $8.07M | $7.82M |
| High Forecast | $9.92M | $22.18M | $8.07M | $7.82M |
| Low Forecast | $9.92M | $22.18M | $8.07M | $7.82M |
| Surprise % | - | - | - | - |
Opthea's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to OPT last annual SG&A of $NaN (undefined).
Opthea EPS Forecast
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|
| # Analysts | - | - | - | - |
| EPS | - | - | - | - |
| Avg Forecast | $-0.95 | $-1.20 | $2.39 | $-0.97 |
| High Forecast | $-0.95 | $-1.20 | $2.39 | $-0.97 |
| Low Forecast | $-0.95 | $-1.20 | $2.39 | $-0.97 |
| Surprise % | - | - | - | - |
According to undefined Wall Street analysts, Opthea's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to OPT previous annual EPS of $NaN (undefined).
Opthea Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| ANTX | AN2 Therapeutics | $1.04 | $8.75 | 741.35% | Buy |
| AVTE | Aerovate Therapeutics | $1.90 | $13.00 | 584.21% | Hold |
| MOLN | Molecular Partners | $5.22 | $29.00 | 455.56% | Buy |
| OPT | Opthea | $3.15 | $14.00 | 344.44% | Buy |
| ANEB | Anebulo Pharmaceuticals | $2.08 | $6.00 | 188.46% | Buy |
| MLYS | Mineralys Therapeutics | $11.76 | $30.00 | 155.10% | Buy |
| RZLT | Rezolute | $5.25 | $13.00 | 147.62% | Buy |
| ACRV | Acrivon Therapeutics | $8.91 | $21.50 | 141.30% | Buy |
| ELYM | Eliem Therapeutics | $8.46 | $13.00 | 53.66% | Buy |
| ADAG | Adagene | $3.49 | $5.00 | 43.27% | Buy |
| CYT | Cyteir Therapeutics | $3.02 | $2.00 | -33.77% | Sell |
OPT Forecast FAQ
Is Opthea a good buy?
Yes, according to 5 Wall Street analysts, Opthea (OPT) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 80.00% of OPT's total ratings.
What is OPT's price target?
Opthea (OPT) average price target is $14 with a range of $14 to $14, implying a 344.44% from its last price of $3.15. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Opthea stock go up soon?
According to Wall Street analysts' prediction for OPT stock, the company can go up by 344.44% (from the last price of $3.15 to the average price target of $14), up by 344.44% based on the highest stock price target, and up by 344.44% based on the lowest stock price target.
Can Opthea stock reach $5?
OPT's average twelve months analyst stock price target of $14 supports the claim that Opthea can reach $5 in the near future.
What are Opthea's analysts' financial forecasts?
OPT's analysts financial forecasts for the fiscal year (Jun 2024) are as follows: average revenue is $264.51K (high $264.51K, low $264.51K), average EBITDA is $-265K (high $-265K, low $-265K), average net income is $7.94M (high $7.94M, low $7.94M), average SG&A $38.07M (high $38.07M, low $38.07M), and average EPS is $0.217 (high $0.217, low $0.217).